Benjamin Maynor, Ph.D. is currently serves as the Vice President, Research at Liquidia Technologies, a nanotechnology company in the Research Triangle Park, NC that focuses on the production of drug delivery systems for ophthalmology, vaccines, and pulmonary therapeutics. As part of his responsibilities he also leads Liquidia’s programs for small molecule/biologic drug delivery. Ben is a co-inventor of Liquidia's PRINT technology. He joined Liquidia in 2005 and has initiated several new technology initiatives at Liquidia, including programs in ophthalmology, respiratory drug delivery, and other therapeutic areas. He received a Ph.D. in Chemistry from Duke University, where he focused on nanofabrication, nanostructure synthesis and materials chemistry. He also holds a B.A. in Chemistry from Harvard University. He has co-authored over 20 peer-reviewed publications in the fields of nanotechnology, colloid science, and drug delivery and has been a co-inventor on several patents and patent applications in the fields of nanotechnology and drug delivery.